Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis	Benralizumab (Fasenra; MEDI563)	Eosinophilic granulomatosis with polyangiitis	Cardiovascular System , Immunology	2022	View \| Download
Benralizumab for treating hypereosinophilic syndrome	Benralizumab (Fasenra; MEDI563)	Hypereosinophilic syndrome (HES)	Immunology	2023	View \| Download
Benralizumab for treating eosinophilic oesophagitis in people aged 12-65 years	Benralizumab (Fasenra; MEDI563)	Eosinophilic oesophagitis	Gastroenterology	2022	View \| Download
Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)	Benralizumab (Fasenra; MEDI563)	Chronic obstructive pulmonary disease (COPD)	Respiratory System	2017	View \| Download
Benegrastim for treating chemotherapy-induced neutropenia in women with breast cancer	Benegrastim	Breast cancer	Breast Cancer , Immunology , Toxicology	2022	View \| Download
Bempegaldesleukin in combination with nivolumab for previously untreated unresectable or metastatic melanoma	Bempegaldesleukin (NKTR-214; BMS-986321; NEKTAR) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Melanoma	Skin Cancer	2022	View \| Download
Bempedoic acid for primary hypercholesterolaemia or mixed dyslipidaemia in patients unable to reach cholesterol goals with the maximum tolerated dose of a statin	Bempedoic acid (ETC-1002; Nilemdo)	Mixed dyslipidaemia , Primary hypercholesterolaemia	Endocrine Nutritional and Metabolic Disorders	2018	View \| Download
Bempedoic acid (monotherapy) or bempedoic acid in combination with ezetimibe for primary hypercholesterolaemia or mixed dyslipidaemia	Bempedoic acid (ETC-1002; Nilemdo) , Ezetimibe (Ezetrol; MK-0653)	Mixed dyslipidaemia , Primary hypercholesterolaemia	Endocrine Nutritional and Metabolic Disorders	2018	View \| Download
Bempedoic acid (monotherapy) and bempedoic acid/ezetimibe (fixed-dose combination) for primary hypercholesterolaemia or mixed dyslipidaemia	Bempedoic acid (ETC-1002; Nilemdo) , Ezetimibe (Ezetrol; MK-0653)	Mixed dyslipidaemia , Primary hypercholesterolaemia	Endocrine Nutritional and Metabolic Disorders	2018	View \| Download
Bemarituzumab with chemotherapy for previously untreated advanced gastric or gastroesophageal junction cancer	Bemarituzumab (FPA-144;AMG 552)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2024	View \| Download